XOMA Corporation

NASDAQ XOMAO

Download Data

XOMA Corporation Free Cash Flow to Equity (FCFE) 3 year CAGR for the Trailing 12 Months (TTM) ending September 20, 2024

XOMA Corporation Free Cash Flow to Equity (FCFE) 3 year CAGR is NA for the Trailing 12 Months (TTM) ending September 20, 2024. Free Cash Flow to Equity represents the cash flow available to equity shareholders after accounting for capital expenditures and net acquisitions. It indicates the amount of cash flow that can be distributed to shareholders or reinvested in the business. It is useful in assessing the company's ability to generate cash flow for its equity investors. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: XOMAO

XOMA Corporation

CEO -
IPO Date April 12, 2021
Location United States
Headquarters 2200 Powell Street, EmeryVille, CA, United States, 94608
Employees 13
Sector Healthcare
Industry Biotechnology
Description

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Similar companies

XOMAP

XOMA Corp

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email